BioGrit’s Approach

Rapid transmission of an infectious disease can have devastating effects on human life and economic stability.1 The world has been hit by a surge of infectious disease outbreaks in the 21st century, with catastrophic consequences for people’s lives and livelihoods all across.2 According to research presented in an article by S. Mukherjee, at least 30 new infectious diseases have evolved during the past three decades, endangering the lives of millions of people around the world.3

BioGrit will develop a number of prophylactics and therapeutics using recombinant technology to tackle different infectious disease in Canada as highlighted in Figure 2. BioGrit will develop these recombinant proteins using an array of expression systems. The properties and comparison of each of these expression systems is shown Table 1.10,11 The advantages of each of the platform technology (recombinant protein subunit, virus-like particles (VLPs), phage display technology, and lysins) is given in Table 2.11,12,13,14,15 

Although not highlighted, BioGrit can develop type specific vaccine (e.g., HPV vaccine) as per the prevalence and its associated risk. 

To address the global AMR conundrum and in line with WHO’s global action on AMR, BioGrit is developing recombinant lysins for WHO Gram-negative critical category of priority pathogens which are associated with mortality and morbidity.

*Technology developed by Tech invention forwhich BioGritTechnologies Inc has exclusive license and rights for North America

Table 1: Comparison of different expressions systems for the development of recombinant proteins (prophylactics
and therapeutics)

Table 2: Advantages of our platform techologies

References

  1. Barac A, Poljak M, Ong DSY. Editorial: Innovative Approaches in Diagnosis of Emerging/Re-emerging Infectious Diseases. Front Microbial. 2020;11:619498. Published 2020 Dec 3. doi:10.3389/fmicb.2020.619498.
  2. Baker RE, Mahmud AS, Miller IF, et al. Infectious disease in an era of global change. Nat Rev Microbial. 2022;20(4):193-205. doi:10.1038/s41579-021-00639-z.
  3. Mukherjee S. Emerging Infectious Diseases: Epidemiological Perspective. Indian J Dermatol. 2017;62(5):459-467. doi:10.4103/ijdijD_379_17.
  4. Srivastava S, Singh PK, Vatsalya V, Karch RC. Developments in the Diagnostic Techniques of Infectious Diseases: Rural and Urban Prospective. Adv Infect Dis. 2018;8(3):121-138. doi:10.4236/aid.2018.83012.
  5. Kelly-Cirino CD, Nkengasong J, Kettler H, et al. Importance of diagnostics in epidemic and pandemic preparedness. BMJ Glob Health. 2019;4(Suppl 2):eoo1179. Published 2019 Jan 29. doi:10.1136/bmjgh- 2018-001179.
  6. Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat Med. 2021;27(4):591-600. doi:1038/s41591-021-01301-o.
  7. Grennan D, Varughese C, Moore NM. Medications for Treating Infection. JAMA. 2020;323(1):100. doi:10.1001/jama.2019.17387.
  8. What are anti-infectives? https://www.pfier.com/science/therapeutic-areas/anti-infectives/about-anti%2oso,anti%2Dinfectives%2C%2owe%20can%3A& text= Treat%20m i nor%20 i nfections%20an d%20most,d iseases%2C%20like%20pn eumon ia%20or%2otuberculosis. Last accessed 15th July 2022.
  9. Sparrow E, Friede M, Sheikh M, Torvaldsen S. Therapeutic antibodies for infectious diseases. Bull World Health Organ. 2017;95(3):235-237. doi:10.2471/BLT. 16.178061.
  10. Tripathi NK, Shrivastava A. Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development. Front Bioeng Biotechnol. 2019;7:420. Published 2019 Dec 20. doi:10.3389/fbioe.2019.00420.
  11. Kumraj G, Pathak S, Shah S, et al. Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward. Hum Vaccin lmmunother. 2022;18 (1):2020529. doi:10.1080/21645515.2021.2020529.
  12. Alfaleh MA, Alsaab HO, Mahmoud AB, et al. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Front lmmunol. 2020;11:1986. Published 2020 Aug 28. doi:10.3389/fimmu.2020.01986.
  13. Nagano K, Tsutsumi Y. Phage Display Technology as a Powerful Platform for Antibody Drug Discovery. Viruses. 2021;13(2):178. Published 2021 Jan 25. doi:10.3390/ v13020178.
  14. Ercan I, Tufekci KU, Kara ca E, Gene S, Gene K. Peptide Derivatives of Erythropoietin in the Treatment of Neuroinflammation and Neurodegeneration. Adv Protein Chem Struct Biol. 2018;112:309-357. doi:10.1016/bs.apcsb.2018.01.007.
  15. Vazquez R, Garcfa E, Ga ref a P. Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials. Front lmmunol. 2018;9:2252. Published 2018 Oct 16. doi:10.3389/fimmu.2018.2252.